Trials / Terminated
TerminatedNCT00677924
Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal Cancer
A Dose-Escalation, Randomized Phase I/II Trial of Zalutumumab - a Human Monoclonal Anti-EGF Receptor Antibody - With or Without Irinotecan Chemotherapy in Cetuximab Refractory Colorectal Cancer Patients Who Have Failed Standard Chemotherapy and Progressed During or Within 3 Months of Stopping Cetuximab-Based Therapy
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Genmab · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to determine the safety and efficacy of Zalutumumab alone or in combination with Irinotecan for the treatment of patients with Colorectal Cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zalutumumab | Solution for infusion |
Timeline
- Start date
- 2008-04-01
- Primary completion
- 2009-04-01
- Completion
- 2009-04-01
- First posted
- 2008-05-15
- Last updated
- 2023-07-18
- Results posted
- 2011-12-23
Locations
3 sites across 1 country: Belgium
Source: ClinicalTrials.gov record NCT00677924. Inclusion in this directory is not an endorsement.